These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 27897303)

  • 21. Cost-effectiveness of subthalmic nucleus deep brain stimulation for the treatment of advanced Parkinson disease in Hong Kong: a prospective study.
    Zhu XL; Chan DT; Lau CK; Poon WS; Mok VC; Chan AY; Wong LK; Yeung JH; Leung MC; Tang VY; Wong RK; Yeung C
    World Neurosurg; 2014 Dec; 82(6):987-93. PubMed ID: 25175275
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The cost-effectiveness of deep brain stimulation in combination with best medical therapy, versus best medical therapy alone, in advanced Parkinson's disease.
    Eggington S; Valldeoriola F; Chaudhuri KR; Ashkan K; Annoni E; Deuschl G
    J Neurol; 2014 Jan; 261(1):106-16. PubMed ID: 24158271
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cost-effectiveness analysis of entacapone in Parkinson's disease: a Markov process analysis.
    Nuijten MJ; van Iperen P; Palmer C; van Hilten BJ; Snyder E
    Value Health; 2001; 4(4):316-28. PubMed ID: 11705299
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Deep Brain Stimulation for Parkinson's Disease with Early Motor Complications: A UK Cost-Effectiveness Analysis.
    Fundament T; Eldridge PR; Green AL; Whone AL; Taylor RS; Williams AC; Schuepbach WM
    PLoS One; 2016; 11(7):e0159340. PubMed ID: 27441637
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Economic Analysis of Deep Brain Stimulation in Parkinson Disease: Systematic Review of the Literature.
    Becerra JE; Zorro O; Ruiz-Gaviria R; Castañeda-Cardona C; Otálora-Esteban M; Henao S; Navarrete S; Acevedo JC; Rosselli D
    World Neurosurg; 2016 Sep; 93():44-9. PubMed ID: 27216925
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Advanced Parkinson's disease: clinical characteristics and treatment. Part II.
    Kulisevsky J; Luquin MR; Arbelo JM; Burguera JA; Carrillo F; Castro A; Chacón J; García-Ruiz PJ; Lezcano E; Mir P; Martinez-Castrillo JC; Martínez-Torres I; Puente V; Sesar A; Valldeoriola-Serra F; Yañez R
    Neurologia; 2013; 28(9):558-83. PubMed ID: 23880230
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Duopa--a carbidopa/levodopa enteral suspension for Parkinson's disease.
    Med Lett Drugs Ther; 2015 Aug; 57(1474):112. PubMed ID: 26218794
    [No Abstract]   [Full Text] [Related]  

  • 28. Cost-effectiveness of deep brain stimulation in patients with Parkinson's disease.
    Dams J; Siebert U; Bornschein B; Volkmann J; Deuschl G; Oertel WH; Dodel R; Reese JP
    Mov Disord; 2013 Jun; 28(6):763-71. PubMed ID: 23576266
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pramipexole v. levodopa as initial treatment for Parkinson's disease: a randomized clinical-economic trial.
    Noyes K; Dick AW; Holloway RG;
    Med Decis Making; 2004; 24(5):472-85. PubMed ID: 15358996
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Use of advanced therapies for Parkinson's disease in Norway.
    Ezat B; Pihlstrøm L; Aasly J; Tysnes OB; Egge A; Dietrichs E
    Tidsskr Nor Laegeforen; 2017 May; 137(9):619-623. PubMed ID: 28468476
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Selecting deep brain stimulation or infusion therapies in advanced Parkinson's disease: an evidence-based review.
    Volkmann J; Albanese A; Antonini A; Chaudhuri KR; Clarke CE; de Bie RM; Deuschl G; Eggert K; Houeto JL; Kulisevsky J; Nyholm D; Odin P; Østergaard K; Poewe W; Pollak P; Rabey JM; Rascol O; Ruzicka E; Samuel M; Speelman H; Sydow O; Valldeoriola F; van der Linden C; Oertel W
    J Neurol; 2013 Nov; 260(11):2701-14. PubMed ID: 23287972
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pharmacoeconomic analysis of using Sinemet CR over standard Sinemet in parkinsonian patients with motor fluctuations.
    Hempel AG; Wagner ML; Maaty MA; Sage JI
    Ann Pharmacother; 1998 Sep; 32(9):878-83. PubMed ID: 9762373
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Treatment possibilities in advanced Parkinson's disease].
    Takáts A; Nagy H; Radics P; Tóth A; Tamás G
    Ideggyogy Sz; 2013 Nov; 66(11-12):365-71. PubMed ID: 24555235
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Pharmacoeconomic aspects of using levodopa/carbidopa intestinal gel in Parkinson's disease].
    Rudakova AV; Yakupov EZ
    Zh Nevrol Psikhiatr Im S S Korsakova; 2014; 114(10):117-21. PubMed ID: 25614914
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cost-utility analysis of deep brain stimulation surgery plus best medical therapy versus best medical therapy in patients with Parkinson's: Economic evaluation alongside the PD SURG trial.
    McIntosh E; Gray A; Daniels J; Gill S; Ives N; Jenkinson C; Mitchell R; Pall H; Patel S; Quinn N; Rick C; Wheatley K; Williams A;
    Mov Disord; 2016 Aug; 31(8):1173-82. PubMed ID: 26846185
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Review of the economic evidence on the use of deep brain stimulation in late stage Parkinson's disease].
    Puig-Junoy J; Puig Peiró R
    Neurologia; 2009 May; 24(4):220-9. PubMed ID: 19603291
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Application of levodopa/carbidopa intestinal gel in advanced Parkinson's disease].
    Toth A; Nagy H; Wacha J; Bereczki D; Takáts A
    Neuropsychopharmacol Hung; 2015 Dec; 17(4):191-6. PubMed ID: 26727723
    [TBL] [Abstract][Full Text] [Related]  

  • 38. EuroInf: a multicenter comparative observational study of apomorphine and levodopa infusion in Parkinson's disease.
    Martinez-Martin P; Reddy P; Katzenschlager R; Antonini A; Todorova A; Odin P; Henriksen T; Martin A; Calandrella D; Rizos A; Bryndum N; Glad A; Dafsari HS; Timmermann L; Ebersbach G; Kramberger MG; Samuel M; Wenzel K; Tomantschger V; Storch A; Reichmann H; Pirtosek Z; Trost M; Svenningsson P; Palhagen S; Volkmann J; Chaudhuri KR
    Mov Disord; 2015 Apr; 30(4):510-6. PubMed ID: 25382161
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [The clinical-pharmacoeconomic study of efficacy of stalevo in the treatment of Parkinson's disease with motor fluctuations].
    Levin OS; Smolentseva IG; Fedorova NV; Chigir' IP; Dokadina LV; Makhnev SO
    Zh Nevrol Psikhiatr Im S S Korsakova; 2008; 108(7):27-34. PubMed ID: 18833115
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cabergoline versus levodopa monotherapy: a decision analysis.
    Smala AM; Spottke EA; Machat O; Siebert U; Meyer D; Köhne-Volland R; Reuther M; DuChane J; Oertel WH; Berger KB; Dodel RC
    Mov Disord; 2003 Aug; 18(8):898-905. PubMed ID: 12889079
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.